TMED9: a potential therapeutic target and prognostic marker in glioma and its implications across pan-cancer contexts
BackgroundThe escalating global cancer burden, projected to reach 35 million new cases by 2050, underscores the urgent need for innovative cancer biomarkers to improve treatment efficacy and patient outcomes. The TMED family, particularly TMED9, has garnered attention for its involvement in cancer p...
Saved in:
| Main Authors: | Benyong Mi, Chaolin Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1558881/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting the Cargo Receptor TMED9 as a Therapeutic Strategy Against Brain Tumors
by: Alaa Daoud Sarsour, et al.
Published: (2025-05-01) -
Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy
by: Zhuangzhi Wang, et al.
Published: (2025-05-01) -
In silico analysis reveals distinct changes in markers of epithelial to mesenchymal transition in glioma subtypes
by: Nives Pećina-Šlaus, et al.
Published: (2025-07-01) -
CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach
by: Yue Peng, et al.
Published: (2025-04-01) -
TMEM150A overexpression was associated with poor prognosis and cancer progression in glioma verified by comprehensive analysis and cell experiments
by: Hao-Qiang Xu, et al.
Published: (2025-07-01)